Navigating Market Access Hurdles

A seminar shares key observations and learnings from the first round of direct price negotiations.

Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework.

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug development landscape.

Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments.

The deal for the San Diego hub provides the CDMO with its first-ever North American manufacturing location for prefilled syringes and cartridges.

The interchangeability designation for Yuflyma, a biosimilar to Humira, may help to improve patient access and reduce costs.